Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment

Ylisaukko-oja, Tero; af Björkesten, Clas Göran; Eberl, Anja; Nuutinen, Heikki; Jussila, Airi; Molander, Pauliina; Koskela, Ritva; Blomster, Timo; Pajala, Markku; Ilus, Tuire; Haiko, Paula; Kovac, Bianca; Silvola, Saija; Smith, Sarah; Jokelainen, Jari; Sipponen, Taina (2024-06-12)
 
Avaa tiedosto
Lataukset: 

URL:
https://doi.org/10.1016/j.heliyon.2024.e32432

Ylisaukko-oja, Tero
af Björkesten, Clas Göran
Eberl, Anja
Nuutinen, Heikki
Jussila, Airi
Molander, Pauliina
Koskela, Ritva
Blomster, Timo
Pajala, Markku
Ilus, Tuire
Haiko, Paula
Kovac, Bianca
Silvola, Saija
Smith, Sarah
Jokelainen, Jari
Sipponen, Taina
Elsevier
12.06.2024

Ylisaukko-oja, T., Af Björkesten, C.-G., Eberl, A., Nuutinen, H., Jussila, A., Molander, P., Koskela, R., Blomster, T., Pajala, M., Ilus, T., Haiko, P., Kovac, B., Silvola, S., Smith, S., Jokelainen, J., & Sipponen, T. (2024). Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biological treatment. Heliyon, 10(12), e32432. https://doi.org/10.1016/j.heliyon.2024.e32432

https://creativecommons.org/licenses/by-nc/4.0/
© 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
https://creativecommons.org/licenses/by-nc/4.0/
doi:https://doi.org/10.1016/j.heliyon.2024.e32432
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on
https://urn.fi/URN:NBN:fi:oulu-202406194721
Tiivistelmä
Abstract

Purpose:
To analyze treatment persistence and treatment outcomes of vedolizumab as first-line biological treatment in Crohn's disease (CD) and ulcerative colitis (UC) patients in a Finnish real-world setting.

Methods:
Observational, retrospective, multi-center chart review study that included adult CD and UC patients initiating vedolizumab as first-line biological treatment between 2014 and 2020.

Results:
The cohort consisted of 54 CD and 69 UC patients. At month 12, treatment persistence was 84.9 % in CD and 64.7 % in UC. Most vedolizumab discontinuations (CD, n = 11; UC, n = 26) were due to inefficacy. Discontinuations due to adverse events were rare (n < 5). Efficacy improvements were observed in treatment persistent patients at 12 months vs. baseline in the Harvey-Bradshaw Index (CD, 1.8 vs. 3.9, p = 0.001), Partial Mayo Score (UC, 1.0 vs. 4.9, p < 0.001), Physician's Global Assessment (CD, 0.9 vs. 1.8, p < 0.001; UC, 0.4 vs. 2.1, p < 0.001), along with positive endoscopic and biochemical outcomes. Clinical remission was 90.9 % vs. 63.0 % for CD, and 81.6 % vs. 12.3 % for UC, while corticosteroid use was 15.9 % vs. 53.7 % for CD, and 14.6 % vs. 92.8 % for UC at 12 months and baseline, respectively.

Conclusion:
Vedolizumab was associated with improvements in efficacy, endoscopic activity, biochemical parameters, and decreased corticosteroid burden when used as a first-line biological treatment.
Kokoelmat
https://creativecommons.org/licenses/by-nc/4.0/
Ellei muuten mainita, aineiston lisenssi on https://creativecommons.org/licenses/by-nc/4.0/